Protein or antibody drug immunogenicity results in the generation of anti-drug antibodies (ADAs), which can reduce drug efficacy, neutralize therapeutic effects or even cause severe immune adverse events to the patient. We provide the fingerprint analysis of anti-drug antibody responses on the epitope level with high-density peptide microarrays based on your protein drug of interest for patient stratification, drug optimization or the development of companion diagnostics.